Navigation Links
Dendreon to Host Conference Call to Provide Updates on U.S. Commercialization Progress, European Strategy for PROVENGE, and Pipeline Progress
Date:1/6/2011

SEATTLE, Jan. 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Friday, January 7, 2011 at 9:00 a.m. ET to provide updates on U.S. commercialization progress, European strategy for PROVENGE, and pipeline progress.Date:

Friday, January 7, 2011Time:

9:00 a.m. ET / 6:00 a.m. PTDial-in:

1-877-548-9590 (domestic) or +1-720-545-0037 (international);conference pass code 35063654Webcast:

www.dendreon.com (homepage and investor relations section)A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-642-1687 or +1-706-645-9291 for international callers; the conference ID number is 35063654. The replay will be available from 12:00 p.m. ET on Friday, January 7 until 11:59 p.m. ET on Monday, January 10.  In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit '/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
2. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
3. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
4. Dendreon Announces Change in Board of Directors
5. Dendreon Announces Election of Dr. David C. Stump to Board of Directors
6. Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
7. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
8. Dendreon Announces Pricing of Common Stock Offering
9. Dendreon Appoints Hans Bishop as Chief Operating Officer
10. Dendreon Announces Proposed Public Offering of Common Stock
11. Dendreon Receives FDA Acknowledgement of Complete Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences ... Decipher Prostate Cancer Classifier, a genomic test for prostate ... node-negative, high-risk men managed by radical prostatectomy without adjuvant ... prostatectomy is relatively uncommon, using tumor genomics to identify ... metastatic disease is an important advance. The study has ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... BioMS Medical Corp (TSX: MS), a leading developer in the ... Stroud, Vice President Regulatory Affairs, will present at the Canadian ... TITLE: "Dirucotide: ... Thursday June 4th ...
... of integrating and sustaining positive change, increasing wellnessWASHINGTON, ... stress can wreak havoc on a body,s systems. ... change paradigm helps individuals cultivate greater wellness, make ... of life in the face of challenges.The approach, ...
... presenting at the Global Crop Protection Summit and exposition on 15-17th ... ... London, UK (PRWeb UK) - Pira International and ... Protection Summit in Edinburgh, Scotland on 15 - 17 September 2009. ...
Cached Biology Technology:BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences 2Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress 2Call for papers for Pira International's Global Crop Protection Summit 2009 2
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... brain, but they also leave behind in the bloodstream a ... the future to direct better treatment for schizophrenia and other ... study is among the first to use metabolomics -- the ... processes -- to look at a psychiatric disease and its ...
... Research Institute on Addictions (RIA) is investigating the “brain’s ... stress, stress-related behavior and anxiety. , A five-year, $1.7 ... is supporting this investigation. , “It is widely ... use and abuse marijuana is to relieve stress,?according to ...
... generators (dopaminergics) in brain cells has produced improvement in ... tests carried out with monkeys by the Navarra University ... at the Hospital and at the other Navarra University-based ... , The results have been published in the latest ...
Cached Biology News:Chemical maps hint at drug's effects on schizophrenia 2Chemical maps hint at drug's effects on schizophrenia 3Implanting dopamine generators in brain cells obtains improvement in Parkinson's in monkeys 2Implanting dopamine generators in brain cells obtains improvement in Parkinson's in monkeys 3
... Security ChemStation is a ... application for data acquisition, ... searching and reporting, addressing ... data security, integrity, and ...
... These handy dispensers save ... glasses, wipers, hats, and other ... benchtop storage bins for small ... and manufacturing. Clear acrylic. Open-slot ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Soil Nematode microRNA Microarray contains all ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: